Reslizumab in patients with severe asthma who failed to respond to omalizumab

Registry ID

EUCTR2016-004459-65

Source registry

EUCTR

Status

Ongoing

Phase

PHASE2

Sponsor

Respira. Fundación Española del Pulmón (SEPAR)

Start date

2017-03-20

Last update

2026-08-16

Conditions

• Severe asthma

Summary

To determine the effect of reslizumab (3mg/kg) administered every four weeks on asthma symptoms at week 24.

Locations

• , , Spain

View on source registry